title: Regression of iris neovascularization after subconjunctival injection of bevacizumab.
abstract: To describe three cases of neovascular glaucoma (NVG) where iris or angle neovascularization regressed remarkably after subconjunctival bevacizumab injections used as the initial treatment before pan retinal photocoagulation (PRP) and/or filtering surgery. Three consecutive NVG patients whose intraocular pressure (IOP) was not controlled with maximal medication were offered an off-label subconjunctival injection of bevacizumab (2.5-3.75 mg/0.1-0.15 mL, Avastin). Bevacizumab was injected into the subconjunctival space close to the corneal limbus in two or three quadrants using a 26-gauge needle. Serial anterior segment photographs were taken before and after the injection. Following subconjunctival injection of bevacizumab, iris or angle neovascularization regressed rapidly within several days. Such regression was accompanied by lowering of IOP in all three cases. The patients underwent subsequent PRP and/or filtering surgery, and the IOP was further stabilized. Our cases demonstrate that subconjunctival bevacizumab injection can be potentially useful as an initial treatment in NVG patients before laser or surgical treatment.
authors.affiliation: Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.
authors.forename: Na Kyung
authors.initials: NK
authors.lastname: Ryoo
authors.forename: Eun Ji
authors.initials: EJ
authors.lastname: Lee
authors.forename: Tae-Woo
authors.initials: TW
authors.lastname: Kim
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D003228:Conjunctiva; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D056965:Injections, Intraocular; D007499:Iris Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
keywords: Bevacizumab; Neovascular glaucoma; Subconjunctival injection
references.citation: J Glaucoma. 2009 Oct-Nov;18(8):589-94
references.pmid: 19826387
references.citation: Br J Ophthalmol. 2009 May;93(5):589-93
references.pmid: 19074917
references.citation: Cornea. 2010 Jun;29(6):691-3
references.pmid: 20458243
references.citation: Cornea. 2011 Jan;30(1):60-6
references.pmid: 20847676
references.citation: Ophthalmology. 2008 Oct;115(10):1837-46
references.pmid: 18929163
references.citation: Invest Ophthalmol Vis Sci. 2002 Jun;43(6):1809-16
references.pmid: 12036983
references.citation: J Ocul Pharmacol Ther. 2010 Feb;26(1):49-53
references.pmid: 20148650
references.citation: Retina. 2006 Mar;26(3):352-4
references.pmid: 16508438
references.citation: Am J Ophthalmol. 2006 Dec;142(6):1054-6
references.pmid: 17157590
references.citation: Retina. 2011 Oct;31(9):1835-40
references.pmid: 21878845
references.citation: Clin Ophthalmol. 2011;5:1011-6
references.pmid: 21845026
references.citation: Clin Ophthalmol. 2010 Jul 30;4:773-5
references.pmid: 20689793
references.citation: Can J Ophthalmol. 2009 Aug;44(4):451-6
references.pmid: 19606170
references.citation: Br J Ophthalmol. 2011 Aug;95(8):1111-4
references.pmid: 20702430
references.citation: Eur J Ophthalmol. 2007 Mar-Apr;17(2):269-71
references.pmid: 17415704
references.citation: Jpn J Ophthalmol. 2010 May;54(3):242-4
references.pmid: 20577861
references.citation: J Glaucoma. 2007 Aug;16(5):437-9
references.pmid: 17700285
references.citation: Am J Ophthalmol. 2006 Jul;142(1):158-60
references.pmid: 16815268
references.citation: N Engl J Med. 2011 May 19;364(20):1897-908
references.pmid: 21526923
references.citation: Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4807-13
references.pmid: 19324856
references.citation: J Glaucoma. 2009 Oct-Nov;18(8):632-7
references.pmid: 19826393
references.citation: Br J Ophthalmol. 2006 Nov;90(11):1344-9
references.pmid: 16854824